Pfizer Aktie News

A monthly chart of PFE using Worden's TC2000 Gold shows the stock oversold on a monthly basis. A stock with a 5.8-6% dividend yield in today's market immediately draws attention. Is the dividend sustainable, and will the pharma giant be able to sustain the current $0.42 per quarter ($1.68 per year) dividend pace and also continue to boost that dividend at a $0.04 per year (one penny per quarter...

Pfizer's stock has hit bottom and could see a boost from bird flu fears. Covid-related sales now account for less than 15% of Pfizer's total revenues, de-risking the investment story. Pfizer is cutting $4 billion in annual costs and has raised its EPS target for the year.

Vertex Pharmaceuticals is in the midst of a major diversification plan. Eli Lilly's medicines for diabetes and obesity are incredibly hot sellers.

Pfizer sells more innovative new medicines than any of its peers. Pfizer has raised its dividend payout every year since 2009.

Pfizer's revenue and net income are moving in the wrong direction. However, the drugmaker has been rejuvenating its pipeline.

The "Sell in May and go away" adage suggests selling stocks in May and returning in November, but historical data shows that June and July have been strong months. September is consistently the worst month for the stock market, with unpredictable returns, while November has historically been the best month. Selling stocks should be based on valuation rather than following a seasonal strategy, f...

Pfizer stock is at its lowest price in over 11 years, presenting a potential buying opportunity. The company's valuation is near historically low levels, and consensus analysts expect earnings to stabilize. The structure of price on the chart suggests that Pfizer may see a bounce and potentially reach the $36-$44 range.

Pfizer's recent slump is understandable and not likely a long-term issue. Veeva Systems has a lot to offer its 1,400-plus customers, and they tend to stick around.